EMA recommends four biologicals for market
The European Medicines Agency delays the EU approval of Nivolumab/Ipilimumab in NSCLC and greenlights four biotherapeutics to be marketed in the EU.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1116 entries already.
Entries by Thomas Gabrielczyk
Companies at EFIB set to drive the bioeconomy
/in News/by Thomas GabrielczykIndustrial biotech innovations, presented in at the 11th EFIB in Toulouse, could become the key enabler set to save our planet if supported appropriately.
Targovax reports promising disease-free survival (DFS) data
/in News/by Thomas GabrielczykTargovax ASA has reported promising disease-free survival (DFS) data from Tg01 in resected pancreatic cancer.
EU set to speed up switch to bioeconomy by new action plan
/in News/by Thomas GabrielczykSix years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased […]
Bacterial antigen mimicry drives MS
/in News/by Thomas GabrielczykT cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS).
Sitryx Therapeutics bags $30m in Series A Financing
/in News/by Thomas GabrielczykOxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and […]
Orchard plans to raise US$172m in ADS
/in News/by Thomas GabrielczykBritish gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, […]
Sphingotec raises 20m in growth equity financing
/in News/by Thomas GabrielczykDiagnostics company sphingotec GmbH successfully closed a 20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners.
Sanofi and Evotec launch drug discovery PPP
/in News/by Thomas GabrielczykEvotec and Sanofi have launched a Public Private Partnership (PPP) aimed at partnering with academic groups in early stage drug discovery across multiple therapeutic areas.
Roche providing improved anti-Her2 bispecific antibody
/in News/by Thomas GabrielczykResearchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.